Survey: Drugmakers appear to be shifting focus

01/20/2010 | MSNBC

A survey by Tufts University found that the number of treatments that received orphan-drug designation from the FDA increased from 208 products between 2000 and 2002 to 425 between 2006 and 2008. The data highlight pharmaceutical companies' growing interest in drugs for rare diseases, according to the study.

View Full Article in:

MSNBC

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC